AU612791B2 - Stabilization of 13,14-dihydro-15-ketoprostaglandins - Google Patents

Stabilization of 13,14-dihydro-15-ketoprostaglandins Download PDF

Info

Publication number
AU612791B2
AU612791B2 AU30298/89A AU3029889A AU612791B2 AU 612791 B2 AU612791 B2 AU 612791B2 AU 30298/89 A AU30298/89 A AU 30298/89A AU 3029889 A AU3029889 A AU 3029889A AU 612791 B2 AU612791 B2 AU 612791B2
Authority
AU
Australia
Prior art keywords
dihydro
keto
ester
cyclodextrin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU30298/89A
Other languages
English (en)
Other versions
AU3029889A (en
Inventor
Sachiko Kuno
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ueno Seiyaku Oyo Kenkyujo KK
Original Assignee
Ueno Seiyaku Oyo Kenkyujo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ueno Seiyaku Oyo Kenkyujo KK filed Critical Ueno Seiyaku Oyo Kenkyujo KK
Publication of AU3029889A publication Critical patent/AU3029889A/en
Application granted granted Critical
Publication of AU612791B2 publication Critical patent/AU612791B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU30298/89A 1988-02-26 1989-02-23 Stabilization of 13,14-dihydro-15-ketoprostaglandins Ceased AU612791B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP63045622A JP2597629B2 (ja) 1988-02-26 1988-02-26 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
JP63-45622 1988-02-26

Publications (2)

Publication Number Publication Date
AU3029889A AU3029889A (en) 1989-08-31
AU612791B2 true AU612791B2 (en) 1991-07-18

Family

ID=12724473

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30298/89A Ceased AU612791B2 (en) 1988-02-26 1989-02-23 Stabilization of 13,14-dihydro-15-ketoprostaglandins

Country Status (13)

Country Link
EP (1) EP0330511B1 (OSRAM)
JP (1) JP2597629B2 (OSRAM)
KR (1) KR970005170B1 (OSRAM)
AT (1) ATE79260T1 (OSRAM)
AU (1) AU612791B2 (OSRAM)
CA (1) CA1314483C (OSRAM)
DE (1) DE68902401T2 (OSRAM)
ES (1) ES2044087T3 (OSRAM)
GB (1) GB2216004A (OSRAM)
GR (1) GR3005933T3 (OSRAM)
NZ (1) NZ228111A (OSRAM)
OA (1) OA09236A (OSRAM)
ZA (1) ZA891410B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU639284B2 (en) * 1989-12-28 1993-07-22 Allergan, Inc. The use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420422B1 (en) 1987-09-18 2002-07-16 Sucampo Pharmaceuticals, Inc. Ocular hypotensive agents
DE3876050T2 (de) * 1987-09-18 1993-03-25 Ueno Seiyaku Oyo Kenkyujo Kk Okulare hypotensivagenzien.
US5166178B1 (en) * 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
US5236907A (en) * 1988-10-01 1993-08-17 R-Tech Ueno Ltd. Ocular hypotensive agents
US5212200A (en) * 1987-09-18 1993-05-18 R-Tech Ueno, Ltd. Ocular hypotensive agents
US5565492A (en) * 1988-07-18 1996-10-15 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
ES2213504T1 (es) * 1988-09-06 2004-09-01 Pfizer Health Ab Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular.
US5194429A (en) * 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
EP0580268B1 (en) * 1988-10-01 1998-01-14 R-Tech Ueno Ltd. Ocular hypotensive agents
US5234954A (en) * 1989-07-27 1993-08-10 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
EP0410652B1 (en) * 1989-07-27 1995-05-17 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Use of 15-keto-prostanoic acid derivatives in the manufacture of a medicament for improvement of excretion of potassium ion
ATE121624T1 (de) * 1989-08-09 1995-05-15 Ueno Seiyaku Oyo Kenkyujo Kk Verwendung von prostansäurederivaten zur herstellung von arzneimitteln zur verbesserung der ausscheidung von nichtprotein in die därme.
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
US5256696A (en) * 1989-11-22 1993-10-26 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2039420C (en) * 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
US6184250B1 (en) 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5807892A (en) * 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5698733A (en) * 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6169111B1 (en) 1995-06-07 2001-01-02 Alcon Laboratories, Inc. Conformationally rigid aryl prostaglandins for use in glaucoma therapy
US6096783A (en) * 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
US6211226B1 (en) 1998-12-17 2001-04-03 Alcon Laboratories, Inc. 11-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
WO2004037268A1 (en) 2002-10-23 2004-05-06 Sucampo Ag Prostaglandin compounds for the treatment of obesity
US20080139652A1 (en) 2003-11-07 2008-06-12 Yusuke Sakai Pharmaceutical Composition Containing Prostaglandin
EP1985298A1 (en) 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5910525A (ja) * 1982-06-21 1984-01-20 Teisan Seiyaku Kk プロスタグランジンｅの安定化組成物
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
CA1323364C (en) 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1324129C (en) 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
ES2038289T3 (es) 1987-05-15 1993-07-16 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Utilizacion de 15-ceto-pges para la fabricacion de un medicamento para aumentar la temperatura corporal.
DE3876050T2 (de) 1987-09-18 1993-03-25 Ueno Seiyaku Oyo Kenkyujo Kk Okulare hypotensivagenzien.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU639284B2 (en) * 1989-12-28 1993-07-22 Allergan, Inc. The use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension

Also Published As

Publication number Publication date
EP0330511B1 (en) 1992-08-12
JPH01221317A (ja) 1989-09-04
NZ228111A (en) 1991-02-26
EP0330511A3 (en) 1989-10-18
ES2044087T3 (es) 1994-01-01
AU3029889A (en) 1989-08-31
EP0330511A2 (en) 1989-08-30
GB8904232D0 (en) 1989-04-12
DE68902401T2 (de) 1992-12-10
KR970005170B1 (en) 1997-04-14
GR3005933T3 (OSRAM) 1993-06-07
ATE79260T1 (de) 1992-08-15
CA1314483C (en) 1993-03-16
ZA891410B (en) 1989-11-29
OA09236A (en) 1992-06-30
DE68902401D1 (de) 1992-09-17
KR890012654A (ko) 1989-09-18
GB2216004A (en) 1989-10-04
JP2597629B2 (ja) 1997-04-09

Similar Documents

Publication Publication Date Title
AU612791B2 (en) Stabilization of 13,14-dihydro-15-ketoprostaglandins
US4886788A (en) Cyclodextrin clathrates of carbacyclin derivatives and their use as medicinal agents
US4444788A (en) Pharmaceutically active 9-chloroprostaglandins
CA1264320A (en) Prostaglandin analogues, process for their preparation and pharmaceutical compositions containing them
JPS6228937B2 (OSRAM)
US4479944A (en) Composition containing PGI2 analogs stabilized
CS209909B2 (en) Method of making the prostacycline derivatives
HU181847B (en) Process for producing acid additional salts of 16-beta-mono-quaterner-ammonium derivatives of 2-beta,16-beta-bis-piperidino-androstanes and pharmaceutical compositions containing them as active agents
Krause et al. Biotransformation of the stable prostacyclin analogue, iloprost, in the rat.
HU191057B (en) Process for the production of new carbacycline-derivatives and of the pharmaceutical preparations containing them
US4552875A (en) Novel carbacyclinamides, their preparation and use as medicinal agents
US4315013A (en) Certain pyrrole analogs of prostacyclin derivatives
EP0232126A2 (en) 6-Keto-prostaglandin E1 derivatives
HU190722B (en) Process for producing new carbacycline esters and pharmaceutical compositions containing them
AU620543B2 (en) 6-oxoprostaglandin-e derivatives, process for their production and their pharmaceutical application
HU191197B (en) Process for preparing new carbacycline derivatives and pharmaceutical compositions containing thereof
CS226440B2 (en) Method of preparing 7-oxoprostacycline derivatives
US5374654A (en) 9-substituted carbacyclin derivatives, processes for their preparation, and their use as medicinal agents
DE3428266A1 (de) Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US5157042A (en) 3-oxa-5-fluoro-carbacyclins, their preparation and use as medicinal agents
US5104861A (en) 7-oxoprostacyclin derivatives which are useful as pharmaceuticals
HU196217B (en) Process for production of new vinblastin-ensime-conjugates and their derivatives and medical compounds containing such substances
ATE3298T1 (de) 17-amino-16-hydroxy-steroide der androstan- und estran-reihen und ihre derivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen.
WO1989000990A1 (en) New 9-substituted carbocycline derivatives, process for manufacturing them and their use as drugs
JP2543396B2 (ja) ５，５−ジフルオロ−６−オキソ−ｐｇｅ誘導体

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired